MIPS researcher receives prestigious Humboldt Research Award
Professor Nicolas Voelcker from the Monash Institute of Pharmaceutical Sciences (MIPS) has received a Humboldt Research Award to the value of EUR 60,000 (approximately AUD $94,000).The award has been granted by Germany’s Alexander von Humboldt
Australian researchers drive global call to action to tackle world’s leading cause of death
A team of Australian drug researchers from Monash University, The University of Sydney and La Trobe University have led a global call to action to accelerate new approaches for cardiovascular disease (CVD) drug solutions. CVD is the leading cause of
MIPS and WEHI granted patent for invention to help tackle cancer
An invention developed by a team of researchers from the Monash Institute of Pharmaceutical Sciences and The Walter and Eliza Hall Institute of Medical Research has been granted patent by The European Patent Office and The United States Patent and
Monash University researchers discover potential therapeutic target to reduce diabetes-induced heart failure
Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with The Baker Heart and Diabetes Institute, have discovered a potential therapeutic target which could reduce heart failure and may improve the quality of
New study finds that age and frailty considerably impact prescribing strategies for people with Type 2 Diabetes
A new study led by Monash University has - for the first time - investigated how age, frailty and dementia predict hospital discharge prescribing for people with Type 2 Diabetes (T2D), with the researchers finding that people aged 80+ are
Monash University retains its spot as #2 in the world for Pharmacy and Pharmacology
The 2021 QS World University Rankings by Subject, released today, ranked Monash University number two in the world for Pharmacy and Pharmacology for the second year running.
Monash University and PureTech Health develop novel technology platform that targets drugs to the lymphatics and lymph nodes
Researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) and PureTech Health (LSE: PRTC, Nasdaq: PRTC) have developed a novel technology platform that directly targets gut lymphatics and has great potential to enhance the utility of
Researchers from Monash University make a breakthrough discovery into how migraines are triggered
World first: Researchers from Monash University have harnessed cutting-edge technology to discover the progression of molecular events that lead to migraine – something that, until now, has remained a mystery.